Adenocarcinoma of colon metastatic | Adenocarcinoma of rectum metastatic
Item
histologically or cytologically confirmed metastatic adenocarcinoma of the colon or rectum
boolean
C0338106 (UMLS CUI [1,1])
C1522484 (UMLS CUI [1,2])
C0149978 (UMLS CUI [2,1])
C1522484 (UMLS CUI [2,2])
TNM clinical staging | Recurrent disease
Item
stage iv or recurrent disease
boolean
C3258246 (UMLS CUI [1])
C0277556 (UMLS CUI [2])
Measurable Disease
Item
measurable disease
boolean
C1513041 (UMLS CUI [1])
Disease Progression | Disease recurrence | fluorouracil/leucovorin calcium | Chemotherapy First line treatment Complete
Item
disease progression or recurrence during or after completion of prior first-line chemotherapy with fluorouracil and leucovorin calcium (5-fu/lv)
boolean
C0242656 (UMLS CUI [1])
C0679254 (UMLS CUI [2])
C0278707 (UMLS CUI [3])
C0392920 (UMLS CUI [4,1])
C1708063 (UMLS CUI [4,2])
C0205197 (UMLS CUI [4,3])
irinotecan | oxaliplatin | fluorouracil/leucovorin calcium
Item
prior irinotecan or oxaliplatin as part of the 5-fu/lv regimen or as subsequent therapy allowed
boolean
C0123931 (UMLS CUI [1])
C0069717 (UMLS CUI [2])
C0278707 (UMLS CUI [3])
Prior Therapy Quantity Neoplasm Metastasis
Item
only 2 prior regimens for metastatic disease allowed
boolean
C1514463 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0027627 (UMLS CUI [1,3])
Adjuvant therapy Quantity | Disease Free of
Item
one additional regimen as adjuvant therapy allowed provided patient remained disease-free for > 6 months after completion of therapy*
boolean
C0677850 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0012634 (UMLS CUI [2,1])
C0332296 (UMLS CUI [2,2])
Investigational New Drugs Targeted | cetuximab | bevacizumab
Item
newer, targeted investigational agents (e.g., cetuximab or bevacizumab) are not
boolean
C0013230 (UMLS CUI [1,1])
C1521840 (UMLS CUI [1,2])
C0995188 (UMLS CUI [2])
C0796392 (UMLS CUI [3])
Chemotherapy | Combined Modality Therapy | Cytotoxic agent | Adjuvant therapy Complete failed | Additional Therapy Quantity Neoplasm Metastasis
Item
counted as a chemotherapeutic regimen unless used in combination with a cytotoxic regimen note: *if evidence of failure occurred within < 6 months after completion of adjuvant therapy, patients may have received only 1 additional regimen for metastatic disease
boolean
C0392920 (UMLS CUI [1])
C0009429 (UMLS CUI [2])
C0304497 (UMLS CUI [3])
C0677850 (UMLS CUI [4,1])
C0205197 (UMLS CUI [4,2])
C0231175 (UMLS CUI [4,3])
C1706712 (UMLS CUI [5,1])
C1265611 (UMLS CUI [5,2])
C0027627 (UMLS CUI [5,3])
Metastatic malignant neoplasm to brain Requirement Therapeutic procedure | Disease Progression
Item
no active brain metastases (requiring treatment or progressing)
boolean
C0220650 (UMLS CUI [1,1])
C1514873 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,3])
C0242656 (UMLS CUI [2])
Blood Transfusion
Item
history of blood transfusion within 14 days
boolean
C0005841 (UMLS CUI [1])
Allopurinol Patient need for
Item
need of concurrent administration of allopurinol
boolean
C0002144 (UMLS CUI [1,1])
C0686904 (UMLS CUI [1,2])
Therapeutic radiology procedure | Chemotherapy
Item
history of radiotherapy or chemotherapy within 4 weeks
boolean
C1522449 (UMLS CUI [1])
C0392920 (UMLS CUI [2])
Condition Exclusion Protocol Compliance | Addictive Behavior Exclusion Protocol Compliance | Family problems Exclusion Protocol Compliance
Item
any psychological or sociological condition, addidtive disorder or family problems that might preclude compliance with the protocol
boolean
C0348080 (UMLS CUI [1,1])
C2828389 (UMLS CUI [1,2])
C0525058 (UMLS CUI [1,3])
C0085281 (UMLS CUI [2,1])
C2828389 (UMLS CUI [2,2])
C0525058 (UMLS CUI [2,3])
C0424960 (UMLS CUI [3,1])
C2828389 (UMLS CUI [3,2])
C0525058 (UMLS CUI [3,3])
medical condition Unstable Interferes with Protocol Compliance | medical condition Severe Interferes with Protocol Compliance
Item
any unstable or severe intercurrent medical condition that in the opinion of th einvestigator might interfere with achievement of study objectives
boolean
C3843040 (UMLS CUI [1,1])
C0443343 (UMLS CUI [1,2])
C0521102 (UMLS CUI [1,3])
C0525058 (UMLS CUI [1,4])
C3843040 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
C0521102 (UMLS CUI [2,3])
C0525058 (UMLS CUI [2,4])
Investigational New Drugs | AG2037
Item
receipt of an investigational agent within 28 days prior to first day of dosing with ag-2037
boolean
C0013230 (UMLS CUI [1])
C0935874 (UMLS CUI [2])
Pregnancy | Breast Feeding
Item
pregnant or breast feeding
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Glycinamide Ribonucleotide Formyltransferase Inhibitor
Item
previous treatment with garft inhibitors
boolean
C1512220 (UMLS CUI [1])
Malignant Neoplasms | Colorectal Carcinoma | curative treatment Skin carcinoma | curative treatment Stage 0 Breast Carcinoma | curative treatment Cervix carcinoma | curative treatment Malignant Neoplasms | Disease Evidence
Item
history of a malignancy (other than colorectal cancer) excpet those treated with curative intent for skin cancer (other than melanoma) or in situ breast or cervical cancer or those treated with curative intent for any other cancer with no evidence of disease for 5 years
boolean
C0006826 (UMLS CUI [1])
C0009402 (UMLS CUI [2])
C1273390 (UMLS CUI [3,1])
C0699893 (UMLS CUI [3,2])
C1273390 (UMLS CUI [4,1])
C0154084 (UMLS CUI [4,2])
C1273390 (UMLS CUI [5,1])
C0302592 (UMLS CUI [5,2])
C1273390 (UMLS CUI [6,1])
C0006826 (UMLS CUI [6,2])
C0012634 (UMLS CUI [7,1])
C3887511 (UMLS CUI [7,2])
Metastatic malignant neoplasm to brain Requirement Therapeutic procedure | Disease Progression
Item
active brain metastases (requiring treatment or progression)
boolean
C0220650 (UMLS CUI [1,1])
C1514873 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,3])
C0242656 (UMLS CUI [2])